October 30, 2025
Definitive Diagnostics Wins NYBio Pitchfest, Hosted by Cooley
Highlighting Strong Investor and Industry Validation
The NYBio Pitchfest is a competitive showcase of early-stage life sciences companies to present to experienced biotech investors, industry leaders, and strategic partners focused on identifying high-potential innovations in healthcare.
October 14, 2025
Protein-Based Liquid Biopsy Platform from Definitive Diagnostics Validated Through Peer-Reviewed Biomedicines Publication
Protein- and immune-based biomarker approach, leveraging abundant, biologically meaningful signals rather than scarce ctDNA fragments, addressing known limitations of DNA-based liquid biopsies in early disease...
May 9, 2025
Definitive Diagnostics’ Proteomics Cancer Test Validated in medRxiv Study
Definitive Diagnostics announced the publication of its first scientific article, detailing a protein-based liquid biopsy platform for multi-cancer detection. The study reports strong diagnostic performance across breast, lung, colorectal, ovarian, and pancreatic cancers, including robust detection of early-stage disease and high tissue-of-origin accuracy.
May 2, 2025
Definitive Diagnostics Wins Healthcare Grand Prize at the 2025 NYU/Berkley Center's "Entrepreneurs Challenge"
The NYU Entrepreneurs Challenge is a highly competitive startup competition that awards early-stage companies with strong innovation, commercialization potential, and real-world impact.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.